MentionFox
Home › funding signals › Phio Pharmaceuticals Corp.
Form D · on the record

Phio Pharmaceuticals Corp. — $1.42M Form D filing, November 2025

Phio Pharmaceuticals Corp. filed a Form D with the Securities and Exchange Commission on 2025-11-12.

Phio Pharmaceuticals Corp. filed a Form D notice of an exempt securities offering with the SEC on November 12, 2025. The filing reports $1.42M sold. Its industry group is Biotechnology. It names Robert Bitterman (Director, Executive Officer), Patricia Bradford (Director), Jonathan Freeman (Director) (SEC Form D, November 12, 2025).

5 more Biotechnology raises in Pennsylvania within 90 days ↓

Is this your company?

Key facts

Run the free check on Phio Pharmaceuticals Corp. →

Sell to companies like Phio Pharmaceuticals Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Phio Pharmaceuticals Corp.

New Form D on file · 2025-11-12 · the record

$1.42M
raise on the record
D
filing
5
investors in
PENNSYLVANIA
based
Open the record →

What the record says

FilingForm D
Filed2025-11-12
Industry groupBiotechnology
Entity typeCorporation
Incorporated inDELAWARE
BasedKING OF PRUSSIA, PENNSYLVANIA
CIK1533040
Accession0001123292-25-000633

Pitching, partnering or investing alongside them? See who really runs and owns Phio Pharmaceuticals Corp.

Free to see. No signup.

Keep reading

More on the people and the money behind Phio Pharmaceuticals Corp., from the filings we hold.

Raised through the same sales agent

H.C. Wainwright & Co, LLC received sales compensation on this raise and on 19 other raises we hold, nearest in date first:

More raises like this

Biotechnology raises by companies based in Pennsylvania, filed within 90 days of this one, largest first.

What do you want to do with Phio Pharmaceuticals Corp.?

Get the full cited report on Phio Pharmaceuticals Corp.

What the filing shows about Phio Pharmaceuticals Corp.

  • 5 investors had already put money in when it filed.
  • The filing names 6 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Phio Pharmaceuticals Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

See a sample report

Who the filing names, and in what role

The filing gives Phio Pharmaceuticals Corp.'s address as 411 Swedeland Road, Suite 23-1080, King Of Prussia, PA 19406.

What the filing says

  • Offered: $25,931,342. Sold: $1,415,796. Left to sell: $24,515,546. (filing)
  • Investors: 5 had already invested. (filing)
  • Date of first sale: November 4, 2025. (filing)
  • Types of securities: Options, warrants or other rights to acquire another security; Securities to be acquired on exercise of an option, warrant or other right. (filing)
  • Item 16: the filing reports that none of the proceeds goes to executive officers, directors or promoters. (filing)
  • On the amounts offered and sold: the filing adds “The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors and placement agent in the private placement under Rule 506(b).” (filing)
  • On sales commissions and finders' fees: the filing adds “$1,116,497.82 in cash and warrants to purchase up to 424,739 shares of common stock (4,500 with an exercise price of $2.8125, 71,145 with an exercise price of $3.1488, 349,094 with an exercise price of $2.875).” (filing)

This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.

Order the Full Report on Phio Pharmaceuticals Corp. See pricing

Is Phio Pharmaceuticals Corp. a real, registered company?

Phio Pharmaceuticals Corp. is a registered filer with the SEC (CIK 1533040) and has filed since 2022-11-23. 12 filings are on record, the latest on 2025-11-12.

A filing shows the company exists and what it reports about itself. It is not an audit or a rating.

Who runs Phio Pharmaceuticals Corp.?

Phio Pharmaceuticals Corp.'s Form D of 2025-11-12 names Robert Bitterman, Patricia Bradford, Jonathan Freeman and 3 more as its officers, directors or promoters.

How much has Phio Pharmaceuticals Corp. raised?

Its new offerings report $10.04M sold across 12 offerings, as its own filings state.

Filing history · 12 filings on this registrant
Form D · 2022-11-23 · $2KForm D · 2023-05-02 · $4.01MForm D · 2023-06-13 · $3MForm D · 2023-12-19 · $533KForm D · 2024-07-24 · $136KForm D · 2025-01-03 · $55KForm D · 2025-01-07 · $30KForm D · 2025-01-28 · $153KForm D · 2025-01-28 · $266KForm D · 2025-01-28 · $208KForm D · 2025-08-04 · $232KForm D · 2025-11-12 · $1.42M · this page 2022-11-23 2025-11-12

Each marker is one filing. The larger marker is the filing this page is about.

Biotechnology · by week
This raise, $1.42M, filed week of Nov 10

Trailing twelve months. 764 filings in Biotechnology, totalled by week. The dot is this raise, $1.42M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on Phio Pharmaceuticals Corp.?

What the filing shows about Phio Pharmaceuticals Corp.

  • 5 investors had already put money in when it filed.
  • The filing names 6 people as officers, directors or promoters.

Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Phio Pharmaceuticals Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Phio Pharmaceuticals Corp. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind Phio Pharmaceuticals Corp.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

RSS

Tools for this story

Each opens in a new tab, filled in for Phio Pharmaceuticals Corp.. With no account yet, you sign up free and land on the result.

More on Phio Pharmaceuticals Corp.

Share this page

Is this your company?

Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

Phio Pharmaceuticals Corp.: Raised $1.42M, Form D filed 2025-11-12
Share on LinkedIn Share on X Download image

Cite this page

Permanent URL: https://mentionfox.com/funding/phio-pharmaceuticals-corp-form-d-25000001
Last updated 2026-10-29
Primary record: SEC filing 1 · SEC filing 2
Phio Pharmaceuticals Corp. raised $1.42M — SEC Form D filing, November 2025. MentionFox, 2026-10-29. https://mentionfox.com/funding/phio-pharmaceuticals-corp-form-d-25000001